PSNL

In the past six months, Personalis announced a definitive agreement on July 20, 2026, to be acquired by Tempus AI, Inc. for $16.25 per share, leading to a 13.32% stock price decrease. The Q2 2026 earnings report on August 4, 2026, showed an EPS miss but revenue exceeded analyst estimates. The Q1 2026 earnings report on May 7, 2026, highlighted significant clinical volume growth, especially for its NeXT Personal test. The company secured milestone Medicare coverage for cancer recurrence surveillance in lung cancer patients in Q1 2026, adding to existing breast cancer coverage. On July 14, 2026, Personalis announced accelerating global expansion with UKCA Marking for NeXT Personal® and enabled global biopharma support with CE-IVD Marked Specimen Collection Kits in June 2026. Over the past 12 months, the stock price gained 181.8%, trading at $16.11 as of September 23, 2026, with a 52-week high of $18.89 and a 52-week low of $4.96.